Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2023
Reporting Period: This filing announces financial results for the three and nine months ended September 30, 2023. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. The filing text itself does not contain specific numerical values for:
- Revenue
- Net Profit or Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Note: Specific financial figures are not present in the 8-K text provided; they are contained within the referenced press release.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It directs investors to the press release dated November 13, 2023, for the announcement of results for the three and nine months ended September 30, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding Q3 2023 results but does not include specific management commentary, forward-looking guidance, or risk factors in the text provided.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2023) for actual revenue, net loss, and cash burn figures.
- Verify the company's cash runway and liquidity status as reported in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm the status of the redeemable warrants (REVBW) and their exercise price of $402.50 per share.